Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper

Blue Sky scratches head lice from portfolio

Blue Sky Venture Capital has exited a head lice treatment company after it entered into a $278 million commercial agreement with Indian-based Dr. Reddy's Laboratories.

LoginGo Premium

Read more: Blue Sky Venture CapitalLaboratoriesAustraliaIndian-based Dr. ReddyBlue Sky Private EquityHatchtechAdelaideAndrew ChampionBlue Sky Alternative InvestmentsDr Elaine SteadGM HotelsGreg MatilandIndependent Pub GroupQueensland Biotechnology FundUniseedUniversity of Melbourne